OBJECTIVE: To evaluate the effect of insulin treatment on health care utilization among type-II diabetics. More aggressive glucose control treatment, particularly with insulin, is known to slow diabetic patients' disease progression. Does it also reduce health care utilization and cost in the short run? METHODS: Medical, pharmacy, and laboratory claims for 369 type-II diabetes patients enrolled in a single managed care plan were evaluated. Patients were continuously eligible for at least two years between June, 2001 and June, 2004. Separate variables were computed for each year. The propensity score (PS) calculated with classification and regression trees (C&RT) was used to calculate the probability of receiving insulin treatment, using year one health status, demographics, and HgA1c laboratory values. These probabilities were then used as weights in the regression of total health care costs and ambulatory costs in year two on an array of variables including insulin use. RESULTS: Insulin treatment does not benefit all groups of patients equally. Patients over the age of 60 benefit significantly from insulin treatment with a reduction in total health care cost of 60.5% (p = 0.0007) and a reduction in ambulatory cost of 60.9% (p = 0.0008) compared to younger diabetic patients (age < 60). CONCLUSION: Diabetic patients age 60 or above and the health care payers would greatly benefit from better glucose control through insulin treatment.
disease management program. As such, future efforts should be developed to increase retention in disease management programs designed for Medicaid recipients.
PDB29 THE EFFECT OF INSULIN TREATMENT ON HEALTH CARE UTILIZATION IN TYPE-II DIABETES
Thiebaud P 1 , Nichol MB 1 , Patel BV 2 1 University of Southern California, School of Pharmacy, Los Angeles, CA, USA; 2 MedImpact Healthcare Systems, Inc, San Diego, CA, USA OBJECTIVE: To evaluate the effect of insulin treatment on health care utilization among type-II diabetics. More aggressive glucose control treatment, particularly with insulin, is known to slow diabetic patients' disease progression. Does it also reduce health care utilization and cost in the short run? METHODS: Medical, pharmacy, and laboratory claims for 369 type-II diabetes patients enrolled in a single managed care plan were evaluated. Patients were continuously eligible for at least two years between June, 2001 and June, 2004 . Separate variables were computed for each year. The propensity score (PS) calculated with classification and regression trees (C&RT) was used to calculate the probability of receiving insulin treatment, using year one health status, demographics, and HgA1c laboratory values. These probabilities were then used as weights in the regression of total health care costs and ambulatory costs in year two on an array of variables including insulin use. RESULTS: Insulin treatment does not benefit all groups of patients equally. Patients over the age of 60 benefit significantly from insulin treatment with a reduction in total health care cost of 60.5% (p = 0.0007) and a reduction in ambulatory cost of 60.9% (p = 0.0008) compared to younger diabetic patients (age < 60). CONCLUSION: Diabetic patients age 60 or above and the health care payers would greatly benefit from better glucose control through insulin treatment.
PDB30 TREATMENT PATTERNS AMONG PATIENTS WITH DIABETES ON METFORMIN AND SULFONYLUREA COMBINATION THERAPY
Pietri G 1 ,Yin D 2 , Lyu R 2 1 Rutgers University, Piscataway, NJ, USA; 2 Merck & Co., Inc, Whitehouse Station, NJ, USA OBJECTIVES: Diabetes is a progressive disease that often requires periodic intensification of treatment to control hyperglycemia. The objective of this study is to evaluate therapy changes after initiation of metformin and sulfonylurea combination therapy. METHODS: This was a retrospective analysis of data derived from the IMS Mediplus UK primary care database. Patients were selected using the following criteria: type-2 diabetes diagnosis, age ≥30 years at diagnosis, initiation of OHA combination with MF and SU between January 1, 1997 and March 31, 2003. Patients with prior insulin prescription were excluded. RESULTS: A toal of 6616 patients were included, with a mean age of 62.82 years (±12.12) and 56.3% of male; 2603 patients (39.39%) had a history of macrovascular events and 647 (9.79%) had microvascular events. Hypertension (78.39%) and dyslipidemia (59.89%) were also common among these patients. The average follow-up was about 36.7 months. After three years of initiating metformin and sulfonylurea combination therapy, 54.8% had changed their therapy, either by discontinuing one or both initial agents, adding a third oral agent or receiving insulin. No patient remained on the initial combination after 6.5 years. Approximately 8-11% of patients changed therapy every six-months during the first five-years. By the end of two years, about 14.1% have required insulin therapy and 10% had switched to another OHA combination therapy. Approximately 46.9% of patients were prescribed insulin therapy after seven-years. CONCLUSION: In this cohort of diabetic patients managed by GPs in the UK, a large number of patients require additional oral anti-hyperglycemic agents or insulin to manage their hyperglycemia. More effective therapies are needed in order to better manage these patients.
PDB31 FACTORS ASSOCIATED WITH HEALTH CARE COST SAVING IN PATIENTS WITH DIABETES TO THE CALIFORNIA MEDICAID POPULATIONS (MEDI-CAL)
Chaikledkaew U 1 , Johnson KA 2 1 Mahidol University, Payathai, Bangkok, Thailand; 2 University of Southern California, Los Angeles, CA, USA OBJECTIVE: To investigate factors associated with health care cost saving in patients with diabetes to the California Medicaid Populations (Medi-Cal). METHODS: A retrospective study was conducted by using claims data from January, 1995 to December, 2000. Dependent variable was total health care cost. Historical data including demographic factors, health care cost and utilization, diabetes drug treatment, follow-up services based on diabetic guidelines, medication compliance, complications, and comorbidities were used as independent variables. The generalized estimating equation method was used to analyze the panel data. RESULTS: Various factors have a significant association with health care cost savings to MediCal. Patients taking both insulin and oral hypoglycemic drugs or patients having drug dose increased had health care costs higher by $1210 and $141, respectively. Patients having oral hypoglycemic or insulin, antihypertensive, or lipid lowering drugs added also had health care costs higher by $264, $528, or $199, respectively. In addition, patients having drugs changed to different classes or to insulin had health care costs higher by $1018. However, patients having one percent of medication compliance increased had health care costs lower by $7 in next six-month period. Moreover, patients having office visits based on diabetic guidelines or patients having glucose monitoring strip had health care costs lower by $730 or $258 in next six-month period, respectively. In addition, patients having lab tests [e.g., HbA1C test every six-months ($121), cholesterol check up every year ($472), or dilated eye check-up every year ($260)] could lower costs in the future. CONCLUSIONS: Medi-Cal policy makers may implement some disease management programs or health policy on patients who have drug treatment problems and patients without follow-up services based on diabetic guidelines in order to improve patient outcomes and decrease health care costs in the future.
PDB32 THE RELATIONSHIP BETWEEN PATIENT'S TYPE OF PAYMENT AND PRESCRIPTION DRUG COSTS FOR DIABETIC PATIENTS
Ngorsuraches S 1 , Sisang T 2 1 Prince of Songkla University, Hatyai, Songkla, Thailand; 2 Maharaj Nakorn Sri Thammarat Hospital, Muang, Nakorn Sri Thamm, Thailand OBJECTIVE: To examine the relationship between patient's payment type and prescription drug costs for diabetic outpatients at a regional hospital in southern Thailand. METHODS: Patient's profile and prescription for 1454 outpatients who used anti-diabetic drugs between August and September 2002 were collected. The patient's type of payment was divided into two groups, which were patients who paid out-of-pocket and patients who did not pay for their prescriptions. Descriptive and linear regression analyses were used to examine the relationship. RESULTS: Results showed that average drug costs per prescription between patients who paid out-of-pocket and patients who did not pay for their prescriptions were significantly different (p < 0.05). The average anti-diabetic drug cost of the patients who paid out-of-pocket was 643.38 Baht ($US 1 = 40Baht) and their average total drug cost was 1853.12 Baht, while the average anti-diabetic drug cost of the patients who did not pay for their prescriptions was 437.91 Baht and their average total drug cost was 990.94 Baht. In drug cost per day basis, the results showed that the average anti-diabetic drug costs per day between two patient groups were not significantly different (p > 0.05). However, their average total drug costs per day were significantly different (p < 0.05). The average total drug cost per day of the patients who paid out-of-pocket was 26.76 Baht, while it was 17.56 Baht for the patients who did not pay for their prescriptions. Linear regression results showed that the patient's type of payment significantly influenced both anti-diabetic and total drug cost per prescription and cost per day. CONCLUSIONS: A significant relationship between patient's payment type and prescription drug costs for diabetic patients was found. The patients who paid out-of-pocket likely obtained more expensive prescription drugs than did the patients who did not pay for their prescriptions.
PDB33 PRESCRIBING TRENDS FOR COMBINATION PRODUCTS IN THE TREATMENT OF TYPE-II DIABETES
Bilek JC 1 , Carlson A 2 , Morris LS 3 1 University of Minnesota, Minneapolis, MN, USA; 2 Data Intelligence, Eden Prairie, MN, USA; 3 IMS Health, Plymouth Meeting, PA, USA OBJECTIVE: To examine prescribing trends of combination oral hypoglycemic therapy for persons with Type-II diabetes using prescription claims. METHODS: Prescribing trends were identified for patients using combination oral hypoglycemic agents for the treatment of diabetes during a three month period beginning November, 2003 -January, 2004 . Persons were considered newly treated with type II diabetes if there were no prescription claims for insulin or oral diabetes agents during a three month period prior to the first prescription for a combination product. Trends in patients already receiving oral hypoglycemic agents or insulin were identified if combination therapy was added after minimally three months of therapy or if oral hypoglycemic combination therapy was added to an existing treatment regimen during the three-month observation period. Current recommendations for use of combination therapy were compared to the results of prescribing trends obtained from administrative data. RESULTS: On average, approximately 661,811 persons were identified with combination therapy on a monthly basis (211,922 in November, 2003; 227,981 in December, 2003; 221,908 in January, 2004) . Of these, on average approximately 130,708 received metformin/rosiglitazone, 491,380 received metformin/ glyburide, and 38,011 received metformin/glipizide. Several prescribing trends were observed for these agents. Despite literature to the contrary, the combination metformin/rosiglitazone was prescribed as initial therapy for 19% of patients receiving prescriptions for that product. Combination products were prescribed as initial therapy for 11% to 19% of patients depending on product. Almost 1% of patients received a combination product plus two or more agents on a monthly basis. A small number of patients received two combination products in their daily regimen. CONCLUSION: Approximately one-fifth of patients receive initial oral hypoglycemic therapy outside of current prescribing recommendations. The prescribing patterns observed from this data suggest the need for treatment regimen management and for plans to carefully study the economic impact of multiple regimen treatments.
PDB34 NEEDLESTICK INJURY IN NURSES CARING FOR PATIENTS WITH DIABETES
Pashos CL 1 , Nicklasson L 2 , Lee JM 3 , Botteman MF 4 , Cobden D 2 1 Abt Associates Inc, Lexington, MA, USA; 2 Novo Nordisk Inc, Princeton, NJ, USA; 3 Abt Associates Inc, Bethesda, MD, USA; 4 PharMerit, Bethesda, MA, USA Objective: To quantify the incidence and risk of needlestick injury (NI) in nurses caring for patients with diabetes. METHODS: Four hundred nurses caring for patients with diabetes in 381 hospitals throughout the United States reported data on their experience with NI, focusing on those occurring within the past year. If respondents experienced multiple NI during this period, detailed data were collected on the most recent event. RESULTS: Of the 400 nurses, 313 (78.3%) reported having ever had a NI, 110 (27.5%) reported having had a NI within the last twelve months, and 44 (40% of those 110) reported multiple NI. Nearly two-thirds of these injuries (n = 73; 66.4%) were punctures that drew blood, resulting in one case of contracted hepatitis C. The cumulative annual incidence of NI events was 448 NI per 1000 nurses. Nurses reported the injury in adherence with existing policies in 21.8% of cases. Disposable syringes were involved in 88 (80%) of the events. In half of the injuries (n = 55), the needled device was equipped with a safety feature that was ineffective, primarily because it was not fully activated (n = 47; 85.5%) or it malfunctioned (n = 2 to 5; 3.6% to 9.1%). NI most commonly occurred while nurses were injecting insulin (n = 33; 30%). In the two weeks following their NI, 60.1% of nurses were more afraid of needled devices than before the injury and 41.8% felt anxious, depressed, or stressed. As a direct result of the NI, nurses missed 77 days of work. CONCLUSIONS: This study is the first to show the relatively high risk both of NI and of NI that draws blood among nurses injecting insulin with a disposable syringe. Additionally, this study reveals significant post-NI emotional distress, suggests significant under-reporting of NI to hospital officials, and demonstrates the need for a more effective needle safety device.
PDB35 FACTOR ANALYSIS AND PRELIMINARY VALIDATION OF INSULIN DELIVERY SYSTEM QUESTIONNAIRE
Hayes RP, Lenox SM Eli Lilly & Company, Indianapolis, IN, USA OBJECTIVE: For patients with type-1 diabetes, having a preferred insulin delivery system may lead to better compliance and better clinical and patient-reported outcomes. The purpose of this study was to assess the reliability and validity of the Insulin Delivery System Questionnaire (IDSQ), an instrument developed to measure overall insulin satisfaction and preference for an insulin delivery system. METHODS: The IDSQ was administered to 137 patients with type-1 diabetes at screening, baseline, crossover, and endpoint of a randomized, noninferiority, crossover trial designed to compare the glycemic control of injectable vs. inhaled insulin. Psychometric analyses included internal consistency (Cronbach's alpha), factorial validity (principal component analysis with Promax rotation), discriminant validity (ANCOVA model with baseline score and other covariates), and responsiveness (t-tests). RESULTS: Exploratory factor analysis indicated that there were three factors accounting for 73% of the variance. All items loaded above >0.50 on either Factor one, lifestyle impact; Factor two, ease of dosing; or Factor three, satisfaction/preference with the exception of the "easy to control my blood sugar" (BG) item. Cronbach's alpha coefficients calculated for the factors were 0.93, 0.86, and 0.86,
